Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Diabetic and alcohol-related neuropathy

Neurology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

A hot swollen foot, new ulcer with infection or ischaemia, spreading tissue loss, rapidly progressive motor weakness, severe postural collapse, painless myocardial-ischaemia symptoms or recurrent hypoglycaemia without warning needs urgent multidisciplinary assessment rather than routine neuropathic-pain titration.

Synopsis

Recognise metabolic and alcohol-related nerve injury, prevent ulceration and autonomic harm, address nutrition and dependence, and treat pain without overlooking an atypical second neuropathy.

  • Distal symmetrical diabetic polyneuropathy usually begins in toes with sensory loss, burning or allodynia, spreads proximally and later affects hands when leg involvement is advanced.
  • Loss of protective sensation may be painless and is more dangerous than pain: inspect feet, pulses, skin, deformity and footwear and place risk into the NICE diabetic-foot pathway.
  • Diabetes also causes autonomic neuropathy, entrapment neuropathies, radiculoplexus neuropathy and cranial mononeuropathies; asymmetry or proximal wasting is not routine stocking neuropathy.
  • Optimise glucose safely and manage blood pressure, lipids, smoking, renal disease and weight, but explain that established axonal loss may not reverse quickly.
  • Very rapid improvement in chronic severe hyperglycaemia can rarely precipitate treatment-induced painful and autonomic neuropathy, so severe new pain after a large HbA1c fall deserves review.
  • Alcohol-related neuropathy reflects direct toxicity plus thiamine and other nutritional deficiencies, liver disease and social factors; quantify intake and dietary adequacy non-judgementally.
  • Give parenteral thiamine for suspected Wernicke encephalopathy or high-risk acute illness and follow the alcohol pathway; oral replacement alone is not adequate for Wernicke disease.
  • For neuropathic pain, NICE initial options are amitriptyline, duloxetine, gabapentin or pregabalin, chosen by comorbidity, function, misuse risk and patient preference.
  • Do not anchor on diabetes or alcohol when weakness is rapid, asymmetrical, proximal or demyelinating, because B12 deficiency, CIDP, vasculitis, compression and medicines may coexist.

Key red flags

Loss of protective sensation

Inability to detect monofilament pressure, temperature or injury identifies ulcer risk even if the patient reports no neuropathic pain.

Active Charcot concern

A unilateral hot, red or swollen foot with neuropathy, sometimes after minor trauma and with little pain, needs immediate offloading and specialist diabetic-foot assessment.

Atypical second process

Marked proximal weakness, rapid progression, upper-limb-first disease, asymmetry or generalized demyelinating findings should prompt investigation beyond diabetes or alcohol attribution.

Investigation priorities

01
Full diabetic foot examinationFirst step

Detect ulceration, callus, deformity, infection, ischaemia and loss of protective sensation and assign risk.

Management branches

Foot firstProtect tissue before treating pain

Diabetes or alcohol-related sensory loss affects the feet.

  1. Inspect bare feet, interdigital spaces, nails, callus, deformity, temperature and footwear, assess pulses and protective sensation and ask about prior ulcer or amputation.
  2. Refer ulcer, infection, ischaemia or suspected active Charcot change at the urgency specified by the NICE diabetic-foot pathway and offload where advised.
  3. Provide daily self-inspection, washing, moisturising away from toe spaces, footwear and thermal-injury advice adapted to vision and dexterity.
  4. Arrange podiatry and risk-based surveillance, ensuring pain improvement never substitutes for ongoing protective care.

Key medicines

DuloxetineFor painful diabetic neuropathy, commonly start 30 mg once daily and increase to 60 mg daily if tolerated under current BNF guidance.Review blood pressure, nausea, liver disease, renal function, sexual effects, suicidality and serotonergic interactions; taper gradually when stopping.
PregabalinBegin with a low divided daily dose, adjust for renal function and titrate only to the lowest exposure that gives meaningful functional benefit.Somnolence, dizziness, oedema, weight gain, falls, misuse, dependence and respiratory depression with opioids require controlled supply and gradual withdrawal.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG19 diabetic foot problemsFoot risk, ulcer, infection and active Charcot recognition and referral.
  • NICE CG173 neuropathic painInitial medicines, switching, capsaicin and treatments not to start.
  • NICE NG28 type 2 diabetes managementGlycaemic and cardiovascular risk management relevant to neuropathy.
  • NICE CG100 alcohol physical complicationsThiamine and safe management of alcohol-related acute risk.
  • NICE CG115 alcohol dependence managementAssisted withdrawal and continuing alcohol treatment.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom